Brings More Than Twenty Years of Biopharmaceutical Leadership ExperienceANN ARBOR, Mich., July 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it has appointed Craig Thompson, Chief Executive Officer of Cerevance, to its Board of Directors. Mr. Thompson will serve as an independent director. With Mr. Thompson’s appointment, Esperion’s Board of Directors now comprises eight members. “We are thrilled to welcome Craig to our Board of Directors. With more than two decades of biopharmaceutic ...

Well-established executive with over 20 years of experience building and leading commercial teams across diverse therapeutic markets and geographies Career focused on driving business growth and developing an integrated commercial strategy to deliver results ISELIN, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the appointment of Bob ...

Targeting 75 EH/s by Year-End211 Blocks Won in June, 25% Decrease M/MIncreased BTC Holdings* to 49,940 BTC Miami, FL, July 01, 2025 (GLOBE NEWSWIRE) -- MARA Holdings, Inc. (NASDAQ: MARA) ("MARA" or the "Company"), a leading digital energy and infrastructure company, today published unaudited bitcoin ("bitcoin" or "BTC") production updates for June 2025 and provided its hashrate outlook for the full year. Management Commentary"With 1.7 gigawatts (“GW”) of captive capacity – including 1.1 GW currently operati ...

Core Insights - Nasdaq achieved the highest volume of listings and capital raised in the first half of 2025 since 2021, with 142 IPOs raising a total of $19.2 billion [1][5] - The exchange maintained a strong leadership position, achieving an 86% win-rate for Nasdaq-eligible listings in the U.S. market, marking 46 consecutive quarters of leadership [1][5] - Nasdaq's market value transferred from exchange transfers since 2005 has crossed $3 trillion, with 11 companies transferring their listings in the first half of 2025 [1][5] Listings and Capital Raise - In the first half of 2025, Nasdaq welcomed 142 IPOs, including marquee listings such as CoreWeave, Chime, and Galaxy Digital [5] - The total capital raised through these IPOs was $19.2 billion, the highest for the first half of the year since 2021 [5] - Nasdaq also facilitated 20 SPAC business combinations, achieving a 95% win-rate in the U.S. for SPAC listings [5] Sector Performance - Nasdaq maintained a 100% win-rate for consumer IPOs and an 89% win-rate for healthcare IPOs, with notable listings including Smithfield Foods and Metsera [5] - The exchange continues to be the leading choice for companies in the financial technology, digital assets, and biotech sectors [2][5] Regulatory Environment - Nasdaq is advocating for smart regulatory reforms to enhance the operating environment for public companies and drive capital formation [5] - A new white paper has been published by Nasdaq calling for modernization of the regulatory environment to support public markets and wealth creation [5] Listing Anniversaries - Nasdaq celebrated significant listing anniversaries for several companies, including Huntington Bancshares Inc (40 years) and Cisco Systems, Inc. (35 years) [5]

Transaction Overview - Greif has signed an agreement to sell its Containerboard business for $1.8 billion in cash to Packaging Corporation of America[4] - The transaction reflects a multiple of 8.5x LTM Fiscal Q2-25 Adjusted EBITDA of $212 million[4, 30] - The company expects to achieve a pro-forma leverage ratio below 2.0x after the transaction[4] - The transaction is expected to close by the end of fiscal year 2025[4] Strategic Goals - The company reaffirms its 2027 financial targets of $1 billion Adjusted EBITDA and $500 million Adjusted Free Cash Flow[4] - The company is targeting an Adjusted EBITDA margin of 18%+[21] - The company is shifting its product mix towards higher growth and less cyclical end markets[5, 6] Capital Allocation - The company anticipates annual interest savings of $85 million and annual maintenance CAPEX savings of $25 million[10] - The company plans to allocate capital with 50% towards returning cash to shareholders, 30% towards investing for growth, and 20% towards maintaining a strong foundation[9] - The company is targeting Adjusted EBITDA of $1B+ at 2.0-2.5x leverage[15] 2025 Guidance - The company is raising the low-end of its Adjusted EBITDA guidance to $725 million and Adjusted Free Cash Flow guidance to $280 million[25]

Exhibit 10.1 Execution Version SIXTH AMENDMENT TO THIRD AMENDED AND RESTATED CREDIT AGREEMENT WHEREAS, the Loan Parties have requested that the Existing Credit Agreement be amended as set forth below, subject to the terms and conditions specified in this Amendment; and WHEREAS, the parties hereto are willing to amend the Existing Credit Agreement, subject to the terms and conditions specified in this Amendment. NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein, and f ...

WHEREAS, the parties hereto are willing to amend the Existing Credit Agreement, subject to the terms and conditions specified in this Amendment. NOW, THEREFORE, in consideration of the premises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: Exhibit 10.1 Execution Version SIXTH AMENDMENT TO THIRD AMENDED AND RESTATED CREDIT AGREEMENT THIS SIXTH AMENDMENT TO THIRD AMEND ...

Financial Status and Strategy - CureVac has a strong financial position with €550.9 million in cash as of September 30, 2024, and an expected cash runway into 2028[82, 87] - The company streamlined costs and enhanced financial discipline, including a 30% workforce reduction expected by the end of 2024[8, 85, 88] - CureVac refocused its portfolio on innovation and R&D, concentrating on high-value programs in infectious diseases and oncology[8, 9] - A strategic transformation is on track, with OPEX expected to decrease by over 30% from 2025 onwards, including a €25 million decrease in personnel costs[85] Pipeline and Development - CureVac is advancing key pipeline milestones for novel medicines targeting unmet needs, with a focus on expanding the pipeline in oncology and infectious diseases[10, 14] - In oncology, a new shared-antigen lung cancer program is set to start clinical trials in H2 2025, and personalized cancer vaccines are progressing with the first candidate expected to enter the clinic in H2 2026[14] - For infectious diseases, a new non-respiratory program was initiated for Uropathogenic E coli (UPEC) in urinary tract infections, with promising preclinical data[14] - Respiratory infectious disease programs, including seasonal influenza, avian influenza, and COVID-19, are fully out-licensed to GSK, with Phase 3 starting for seasonal flu in 2025[13, 37, 86] Technology and Manufacturing - CureVac's mRNA platform is versatile, featuring precision mRNA backbone, improved LNP delivery systems, and a strong intellectual property portfolio[12, 13] - The company utilizes advanced delivery systems, including proprietary therapeutic area-specific next-generation lipid nanoparticles, and scalable manufacturing, including The RNA Printer®[12] - CureVac's Infectious Disease LNP offers thermostability for more than 12 months at refrigerator temperature (2-8°C)[60]

本文来自微信公众号：躺平学原理，作者：躺即平德，题图来自：AI生成 "孔乙己的长衫"这个梗，常常用来形容做题家面临学历贬值带来的就业难，但又拉不下脸干低端工作。我自己也经常玩这个梗。此外，因为孔乙己的定型 文太过经典，定型文写多了，其中的经典桥段我都快要背下来了。 但有一说一，我自从中学之后，就没完整看过《孔乙己》的原文。孔乙己的形象以梗和定型文的形式活在我心中。前一阵子，我把孔乙己的原文又看了一 遍，发现虽然网友经常用孔乙己来代指小镇做题家，实际上孔乙己和做题家有本质区别。 首先是孔乙己对自己的研究领域多少沾点情怀，他很热爱科举的内容，也就是儒家思想四书五经之类的东西。不仅以一种教化万民的社会责任感，教小孩 茴有几种写法，甚至还冒着被吊起来打的风险去偷书，他真的，我哭死。 做题家则不同，做题纯粹是起一种功利性作用，很难谈得上热爱。所谓提升一分干掉千人，即使喜欢某个科目，喜欢的也是排位赛打赢或者爬鄙视链时俯 瞰对手的爽感，情绪价值不来源于做题本身。不知道大伙有没有看今年高考时张锡峰的新作，他指出河北人高考的目的就是离开河北。除了全国各地来考 察的校长，我猜没有人体验衡水模式是因为喜欢。 这事我只能说，抛开功利 ...

转自：新华财经 新华财经北京7月1日电（记者余蕊）中国银行研究院1日发布《全球银行业展望报告（2025年第3季 度）》。报告指出，2025年一季度，我国商业银行净息差为1.43%，同比下降0.11个百分点，再次创下 历史新低。但较2024年同期数据，净息差下降趋势已有所收窄。预计2025年前三季度，商业银行利息业 务仍面临一定压力，但下行趋势将有所缓解。 报告预计，2025年前三季度商业银行净利润和营业收入较2024年前三季度基本持平。 编辑：幸骊莎 基于上述分析，报告预计2025年前三季度，我国商业银行利息业务下行趋势将有所缓解。 报告解构了2025年净息差的压力来源：一是LPR下调，推动个人按揭、对公贷款等存量贷款在2025年进 行重定价。二是隐性债务化解相关工作有序推进，置换高成本存量隐性债务将带动净息差下行。三是需 求端疲软加大银行资产业务价格压力。在扩表放缓的背景下，银行同业竞争压力持续增大，对信贷价格 造成一定冲击。 报告指出，与此同时，缓解净息差下行压力的积极因素也在积累，特别是主要银行再度下调存款挂牌利 率。2025年5月，主要银行陆续下调存款挂牌利息，其中工、农、中、建、交五大行活期存款利率 ...